Vaxcyte, Inc.
Nasdaq · Biological Products, (No Diagnostic Substances)
Company Overview
A concise company profile alongside the latest public filing activity.
Vaxcyte is a clinical-stage biotechnology company developing conjugate vaccines, including candidates targeting pneumococcal disease, using its proprietary cell-free protein synthesis platform to engineer broader-spectrum immunizations.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Wassil JimCHIEF OPERATING OFFICER | Sell | $94K | 1,537at $60.89 | Sep 1, 2026 |
| Wassil JimCHIEF OPERATING OFFICER | Sell | $56K | 924at $60.95 | Sep 1, 2026 |
| Wassil JimCHIEF OPERATING OFFICER | Sell | $44K | 713at $61.48 | Sep 1, 2026 |
| Wassil JimCHIEF OPERATING OFFICER | Sell | $19K | 303at $61.42 | Sep 1, 2026 |
| Dhaliwal Harpreet S.Chief Technical Ops Officer | Sell | $935K | 17,000at $55.00 | Aug 5, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
| Member | Chamber | Type | Amount | Date |
|---|---|---|---|---|
| Gilbert CisnerosCA31 | House | Buy | $1,001 - $15,000 | Jul 16, 2026 |
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable PCVX activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.